VISCHER AG has advised Novartis AG in this transaction.
Novartis has signed a collaboration agreement and an option to acquire Cellerys.
The Zurich-based startup is researching an innovative therapy to combat multiple sclerosis (MS). This therapy has the potential to delay the progression of the disease. Under the agreement, Novartis will support the development of the therapy, CLS12311, which is currently in Phase 2 clinical research.
Novartis has the option to acquire Cellerys upon completion of Phase 2 trials in the coming years.
Cellerys was founded in 2015 as a spin-off from the Univer-sity of Zurich by two renowned MS specialists, Roland Martin and Andreas Lutterotti.
The VISCHER team was led by Matthias Staehelin (Picture) with Christian Wyss and Pauline Pfirter (all Corporate/M&A).
Law Firms: VISCHER AG;